Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Aim(s): We evaluate our experience in metastatic WD NET patients (pts) treated with Cp and SSA metronomic regimen.
Materials and methods: From October 2005 to December 2013, 30 WD NET pts with progressive disease after failure of SSA and/or CT, Everolimus, PRRT were treated with Cp and SSA. The primary tumor site was pancreas (P) in 12 pts, gastrointestinal tract (GI) in eight pts, lung (L) in five pts, and unknown (U) in five pts. Pts received Cp 1000 mg/mq/bidie os days 1-14 and SSA (octreotide LAR 30 mg 1 fl im q28 or lanreotide LAR 120 mg 1 fl im q28). Treatment efficacy was evaluated by response rate according to RECIST criteria and in terms of PFS. Safety and tolerability were evaluated by assessing the onset of adverse events and treatment feasibility.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
To read results and conclusion, please login ...
Further abstracts you may be interested in